FUJIFILM Cellular Dynamics competitors

John prides himself as a builder of growing international businesses and organizations, successfully deploying both organic and M&A strategies in doing so. As President & CEO since June 2012, John has lead the turnaround and growth of Codexis Inc, the Nasdaq-listed protein engineering company based in Silicon Valley, California. Prior to Codexis, John worked in various business leadership roles for more than 22 years at Albemarle Corporation, a maker of highly engineered specialty chemicals. Spanning three successive multi-year chapters there, John lead the growth of the company’s largest, billion dollar plus global catalyst business, turned around a struggling half billion dollar fine chemicals business, and expanded and globalized Albemarle’s flame retardants business. A native of New York city, John and his family have lived widely across the USA, and also enjoyed an exciting three year assignment in Tokyo, Japan in the late 1990’s. John received a bachelor’s degree in chemical engineering from the Polytechnic Institute of New York University (now NYU) and an MBA from the Massachusetts Institute of Technology. Outside of work, John proudly boasts about his 30 year marriage, two fabulous children, and four delightful grandchildren. John also has passionately applied himself to help solve the plight of the millions of patients suffering from myalgic encephalomyelitis / chronic fatigue syndrome, and is the Board Chair for the leading patient lead organization for the cause in the US, the Solve ME/CFS Initiative (www.solvecfs.org).

Ryan Spencer is a Board Member at Dynavax Technologies and Chief Executive Officer at Dynavax Technologies and is based in Berkeley, California. He has worked as Senior Director Commercial Operations at Dynavax Technologies; Senior Product Director, HEPLISAV-B at Dynavax Technologies; and Vice President, Corporate Strategy & Commercial Operations at Dynavax Technologies. Ryan attended Universidade Federal de Santa Catarina between 1995 and 1999.

Chang Wang Ph.D is the Co-Founder, Chief Scientific Officer, Owner, CEO, and Chairwoman at United Biomedical,Inc.

Armin Spura is a Chief Executive Officer at Crown bioscience.

Roy Smythe, M.D., is the Chief Executive Officer of SomaLogic, Inc., a leading-edge biotechnology company headquartered in Boulder, Colorado. During the course of his career, he has been an internationally recognized surgeon, biomedical scientist, academician, health system administrator and healthcare business entrepreneur. While in medical school at Texas A&M, he was a Charles A. Dana Foundation Scholar at the University of Pennsylvania School of Medicine and the Wharton School of Business. Following medical school, Smythe trained in general surgery, surgical oncology and thoracic surgery and completed a postdoctoral research fellowship in molecular therapeutics at the University of Pennsylvania. His medical and translational research career then began at the University of Texas MD Anderson Cancer Center, where he was the recipient of NIH and numerous other funding awards. He subsequently chaired the Department of Surgery at Baylor Scott & White Health System and the Texas A&M Health Science Center College of Medicine, where he was the Roney Endowed Chair, and later became the Medical Director of Innovation and Executive Vice President for Institute Development before moving into expanded roles in corporate healthcare. Smythe came to SomaLogic from Royal Philips, where he served as Global Chief Medical Officer for Strategy and Partnerships. Before joining Philips, he served as Chief Medical Officer at Valence Health, a Chicago-based healthcare company. He held the same title previously at AVIA, a healthcare technology accelerator. A highly sought-after lecturer and the author of more than 300 papers, abstracts and essays in academic, literary and humanities publications, Smythe is also currently a member of more than 20 U.S. national learned societies.

Specialties: Board Certification in (1) Oncology, (2) Hematology, and (3) Internal Medicine; Phase 1-3 oncology and hematology clinical trials; global drug development; pharmacovigilance; DSMBs; due diligence; business development; strategic clinical development, alliances and collaborations; translational research; companion diagnostics; interactions with US and ex-US regulatory agencies

Dr. Maynard Howe, as Stemedica Co-Founder and former Chief Executive Officer, brings a richly diverse background to the Company. Along with his brother, Roger, he had previously launched five successful ventures in the medical device, software, testing and measurement, quality and consulting fields. As Founder, Co-Chairman and CEO of Reliant Technologies, he led a team of scientists, engineers and physicians in developing, testing and launching the revolutionary medical laser for skin surgery known as Fraxel, an award winning medical laser technology that has resulted in defining a new category of science called fractional photothermolysis. This new science involves the role of lasers and the patient’s own stem cells in wound healing and derm/plastic surgery. The Fraxel laser, in conjunction with autologous and allogeneic stem cells, is currently being used in new clinical studies to treat scars, burn scars and diabetic ulcers. During his tenure at Reliant Technologies, the company achieved a strong intellectual property position with over 20 patents issued and 40 pending applications. In addition, Reliant had secured 13 FDA clearances, making it one of the premier market leaders with distribution in over 15 countries. While at Reliant, Dr. Howe also led the team responsible for securing funding from individual and institutional investors including: Three Arch Partners, Pinnacle Venture Partners, Meritech Capital Partners, Delphi Ventures and Comerica Bank. Within two months of filing its S1, Reliant was sold to Solta Medical, Inc., a publicly held company (SLTM) that has and continues to pioneer and define the aesthetic industry with its innovative technology. Prior to Reliant, Dr. Howe helped more than fifty Fortune 500 companies coordinate their company-wide quality and customer relationship initiatives. As a senior executive and co-founder of a leading customer and market research company, he was responsible for conducting extensive marketing and branding campaigns, market assessments and trend research in both business-to-business and business-to-consumer environments. Maynard is also co-founder and previous Chairman of BioPharma Scientific, LLC, specializing in the integration of pharmaceutical nanotechnology into the field of nutraceuticals. He has experience in setting up distribution and managing sales channels throughout North America, Europe and parts of Asia for several of the companies he has co-founded. Maynard holds a Bachelor of Science Degree, Master of Science Degree and a Doctorate in Psychology. His ability to recruit world leaders and industry experts and create a culture of innovation and teamwork has contributed to the successes achieved in the businesses he has co-founded and those in which he has provided services as a board member and consultant. Dr. Howe is the author and co-author of numerous articles and top selling business books. He is a nationally and internationally recognized speaker and lecturer. His benchmark book on quality, “Quality on Trial, Bringing Customer Relationships into Focus“, is in its second edition and has been published in several languages. His current book, which he is a co-author, “Miracle of Stem Cells: How Adult Stem Cells are Transforming Medicine“, is in its second printing and in the process of being translated into several languages. Other books include a five part implementation manual series, “Business to Business Marketing Management System“, published by McGraw-Hill. He is a diplomate of the American College of Forensic Examiners and an active Board Member of the USO. Previously he was a Board Member and Chairman of the Advanced Development Committee for Alliant International University. Dr. Howe continues to Chair Doctoral Dissertations in Clinical Psychology and as well as in related Behavioral Science Fields.